Table: Taisho Pharmaceutical HD -2020/21 parent results
May 14 (Reuters)-
Taisho Pharmaceutical Holdings Co Ltd
PARENT-ONLY FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
Year ended Year ended Year to NEXT
Mar 31, 2021 Mar 31, 2020 Mar 31, 2022 YEAR
LATEST YEAR-AGO COMPANY COMPANY
RESULTS RESULTS FORECAST H1 FORECAST
Sales 4.20 6.01
(-30.1 pct) (-61.5 pct)
Operating 2.49 4.13
(-39.8 pct) (-69.8 pct)
Recurring 2.47 4.08
(-39.5 pct) (-70.1 pct)
Net 1.87 3.10
(-39.7 pct) (-89.8 pct)
EPS 23.40 yen 38.81 yen
EPS Diluted 23.37 yen 38.77 yen
Ann Div 100.00 yen 110.00 yen 100.00 yen
-Q2 Div 50.00 yen 50.00 yen 50.00 yen
-Q4 Div 50.00 yen 60.00 yen 50.00 yen
NOTE - Taisho Pharmaceutical Holdings Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4581.T
Recent news on Taisho Pharmaceutical Holdings Co
See all newsBrief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Squeeze Out Price If Taisho Disagrees With Their Demand - Nikkei
Brief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Tender Offer Price If Taisho Disagrees Their Demand - Nikkei
Activist fund Oasis says it may take legal action over Taisho's management buyout
Brief: Curi RMB Capital Opposes Taisho Pharmaceutical HD's Management Buyout
To Retire Treasury Shares Worth 3.65% Of Outstanding Stock On April 10